Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial of LAE002 plus LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

Next Previous
Trial Profile

A phase 3 trial of LAE002 plus LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afuresertib (Primary) ; LAE 001 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 27 May 2024 New trial record
  • 23 May 2024 According to a Laekna Therapeutics media release, company announced that it has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top